Results 161 to 170 of about 103,219 (202)

Osimertinib-induced BRAF mutation in a single metastatic lesion among multiple pulmonary lesions in a case of lung cancer with EGFR exon 19 deletion. [PDF]

Respirol Case Rep
Miura H, Miura J, Goto S, Yamamoto T.
europepmc   +1 more source

Prevalence, risk factors, and BRAF mutation of colorectal sessile serrated lesions among Vietnamese patients. [PDF]

World J Clin Oncol
Vu NTH, Le HM, Vo DT, Vu HA, Le NQ, Ho DDQ, Quach DT.   +6 more
europepmc   +1 more source

Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy. [PDF]

Br J Cancer
Edin S, Gylling B, Li X, Stenberg Å, Löfgren-Burström A, Zingmark C, van Guelpen B, Ljuslinder I, Ling A, Palmqvist R.   +9 more
europepmc   +1 more source

Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. [PDF]

Thorac Cancer
Tamura A, Inaba Higashiyama R, Yoshida T, Satozono Y, Ohe Y.   +4 more
europepmc   +1 more source

Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF

Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF
BRAF mutations are rare driver mutations in non-small cell lung cancer (NSCLC), accounting for 1%–2% of the driver mutations, and the mutation spectrum has a wide range in contrast to other tumors. While V600E is a dominant mutation in melanoma, more than half of the mutations in NSCLCs are non-V600E.
openaire  

Non-V600E BRAF mutation in hairy cell leukemia variant. [PDF]

EJHaem
Vijayanarayanan A, Wang SA, Garces S, Saluja K, Medeiros LJ, Thakral B.   +5 more
europepmc   +1 more source

Histopathological findings of 687 thyroid nodules, suspicious for malignancy on ultrasound, with an indeterminate cytopathological diagnosis after the combination of the Bethesda System and BRAF mutation status. [PDF]

Cytojournal
Meng X, Hou R, Zhang M, Chen J, Zhang K, Li J.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

BRAF mutations in thyroid cancer

Current Opinion in Oncology, 2021
Purpose of review Activating mutations in the mitogen-activated protein kinase (MAPK) pathway play an important role in papillary (PTC) and anaplastic (ATC) thyroid cancer. The aim of this review is to discuss the impact of BRAF mutations on clinical features and treatment of patients with thyroid cancer.
Rafael Selbach, Scheffel, Jose Miguel, Dora, Ana Luiza, Maia   +2 more
openaire   +2 more sources